Business news

Nanopharmaceutical Drugs Market Size Forecasted to Reach Valuation of USD 82.71 Billion by 2027

By Biswas Debanjan

Posted on December 13, 2021

A report of the global nanopharmaceutical drugs shows that the market is expected to be valued at USD 82.71 Billion by 2027, according to a recent study by Emergen Research. The market has benefitted from the increasing demand for effective treatment over cancer. Cancer has a significant impact on social and economic growth all over the world, especially in the U.S., as the country bears the leading cost burden of the disease. In 2020, around 1,806,590 new cancer cases were found in the U.S. alone and around 606,520 deaths are predicted due to the disease.

The advantages of nanopharmaceutical drugs, such as drug accumulation in specific tissue, apoptosis commencement, and ability of targeting lesions/tumor cells are boosting its adoption for clinical research for the treatment of cancer. Increasing demand for clinical trials for development of effective treatments is boosting growth of the global nanopharmaceutical drugs market. Furthermore, the market for nanopharmaceutical drugs is gaining traction owing to the ability of these drugs to overcome limitations of conventional drugs and pharmaceutical agents.

Grab Your Free Sample PDF Copy Now

Key Highlights from the Report

In February 2019, Sanofi and NH TherAGuIX have entered in an agreement for introduction of AGuIX Nanoparticle in the field of cancer treatment. Through this agreement, the NH TherAGuIX will gain industrial expertise of Sanofi for producing active pharmaceutical ingredients (API).
Based on type, the microemulsion formulations sub-segment is dominated the overall market and is estimated to remain dominant in the forecast period. These formulations are considered to be advantageous when compared to conventional oral formulations.
Based on application, the pharmaceutical and biotechnology sub-segment is estimated to hold substantial share in the growth of the market. This growth is attributable to sanction for clinical use varying from drug delivery to and medical devices from respective authority organizations.
Regionally, North America held the largest market share in 2019 and is estimated to remain dominant over the forecast period. This growth is attributable to the higher adoption of advanced diagnostics, established healthcare infrastructure, rising incidences of chronic conditions, and undertaking of various initiatives for awareness about the disease and its treatments.
Key players in the nanopharmaceutical drugs market include AstraZeneca plc, Amgen Inc., Gilead Sciences Inc., F. Hoffmann-La Roche AG, Novartis AG, AbbVie Inc., Pfizer Inc., Johnson & Johnson, Sanofi SA, and Merck & Co. Inc.

Nanopharmaceutical Drugs

Emergen Research has segmented the global nanopharmaceutical drugs market on the basis of type, application, distribution channel, and region:

Type Outlook (Revenue, USD Billion; 2017-2027)
- Liposomes
- Polymeric Micelles
- Microemulsion
- Solid Lipid Nanoparticles
- Nanoemulsion
- Others

Application Outlook (Revenue, USD Billion; 2017-2027)
- Oncology
- Cardiovascular/Physiology
- Anti-inflammatory/Immunology
- Neurology
- Anti-Infective
- Others

Distribution Channel Outlook (Revenue, USD Billion; 2017-2027)
- Hospital Pharmacies
- Retail Off-Line Pharmacies
- Retail On-Line Pharmacies

Regional Outlook (Revenue, USD Billion; 2017-2027)
- North America
  1. U.S.
  2. Canada
  3. Mexico
- Europe
  1. Germany
  2. U.K.
  3. France
  4. BENELUX
  5. Rest of Europe
- Asia Pacific
  1. China
  2. Japan
  3. South Korea
  4. Rest of APAC
- Latin America
  1. Brazil
  2. Rest of LATAM
- Middle East & Africa
  1. Saudi Arabia
  2. U.A.E.
  3. Rest of MEA